Diuretics Flashcards
diuretics acting in the PCT
acetazolamide
mannitol
diuretics acting in the LOH
furosemide
bumetanide
torsemide
diuretics acting in the DCT
hydrochlorothiazide chlorthalidone metolazone quinothazone indapamide spironolactone eplenerone amiloride triamterene
carbonic anhydrase inhibitors (CAIs)
acetazolamide
osmotic diuretics
mannitol
loop diuretics
furosemide
bumetanide
tosemide
benzothiadiazides (thiazide diuretics)
hydrochlorothiazide chlorthalidone quinethazone metolazone indapamide
class I thiazide diuretics
hydrochlorothiazide
chlorthalidone
quinethazone
class II thiazide diuretics
metolazone
indapamide
aldosterone antagonists
spironolactone
eplenerone
K-sparing diuretics
triametrene
amiloride
CAI MOA
inhibit carbonic anhydrase:
- bicarb not reabsorbed
- H+ not regenerated inside the cells
- Na+/H+ antiporter inhibited
- Na+ reabsorption also inhibited
- increased delivery of NaHCO3, NaCl, & H2O to distal tubule
CAI effect on electrolyte excretion
increased excretion: -Na & HCO3- (moderate) -H2O (UF) -K+ increased reabsorption: -Cl-
CAI clinical uses
alkalinize urine (cysteinurea) reduce intraocular pressure seizures (MOA unknown) mountain sickness prophylaxis diuresis (limited)
CAI ADEs
metabolic acidosis (HCO3- loss in urine) hypokalemia (K+ loss in urine)
osmotic diuretics characteristics
small molecules are filtered but not reabsorbed
osmotic diuretics MOA in PCT
osmotically inhibit Na+ & H2O reabsorption
osmotic diuretics MOA in peripheral tissues
increase osmolarity of plasma extract H2O from peripheral tissues decrease blood viscosity increase RBF decrease RBF tonicity
osmotic diuretics MOA in LOH
thin descending limb: impair H2O reabsorption
thin ascending limb: impair NaCl & urea reabsorption
thick ascending limb: interfere with transport
osmotic diuretics effect on electrolyte excretion
increase excretion:
- H2O
- NaCl
- K+
acetazolamide ROA
oral
mannitol ROA
injection
osmotic diuretics clinical uses
dialysis disequilibrium syndrome
reduce intracranial/intraocular pressure
osmotic diuretics ADE
volume overload
osmotic diuretics contraindications
cardiac failure
loop diuretics MOA
inhibit NK2C inhibit macula densa NaCl sensation stimulate prostaglandin biosynthesis increase RBF regulate extraction fraction (maintain GFR) increase renin release
loop diuretics effect on electrolyte excretion
increased excretion:
- Na+ (potent NaCl loss)
- K+
- H+
- Ca2+
- Mg2+
- H2O
loop diuretics effect on RAAS
increase renin release:
- inhibit macula densa
- reflexively activate SNS
- stimulate intrarenal baroreceptors
loop diuretics clinical uses
edema pulmonary edema (acute IV) hypercalcemia protection against renal failure washout of toxins severe HTN (+ other drugs), esp. w/renal insufficiency, cardiac failure, cirrhosis HTN crisis (IV)
furosemide ROA
orally
IV
IM
furosemide characteristics
loop diuretic
secreted by organic acid transporter: impaired secretion in renal disease
wide margin of safety
furosemide pharmacokinetics
onset = 30 min duration = 8hr half-life = 1.5 hr extensively protein bound 65% renal excretion
furosemide ADEs
hypokalemia pH disorders (alkalosis) high BUN hyperglycemia hyperuricemia ototoxicity sialadentitis
da fuk is sialadentitis
inflammation of salivary glands
furosemide interactions
lithium indomethacin probenecid warfarin NSAIDS (will cause diuretic resistance)
bumetanide characteristics
loop diuretic
40x more potent than furosemide
can be used with warfarin
bumetanide ROA
oral
torsemide characteristics
loop diuretic
vasodilator: also lowers BP
longer half-life than other loop diuretics
thiazide diuretic MOA
inhibit Na+Cl-cotransporter (NCCT) in Na+/K+/aldosterone independent segment of distal tubule
thiazide diuretics effect on electrolyte excretion
increase excretion: -Na+ -Cl- -K+ -Mg2+ -titratable acid decrease excretion: -Ca2+
thiazide diuretics clinical uses
diuretic hypercalciurea antihypertensive (+/- other drugs) osteoporosis nephrogenic diabetes insipidus mild/moderate HTN "volume dependent" HTN (low renin levels) HTN w/impaired renal fxn (metolazone&indapamide)
thiazide characteristics
require secretion into tubular fluid
ineffective if GFR less than 30 mL/min
class I thiazide diuretic clinical uses
GFR >60mL/min
class II thiazide diuretic clinical uses
GFR b/t 30-60mL/min
hydrochlorothiazide (HCTZ) ROA
oral
half-life = 2.5h
chlorthalidone ROA
oral
half-life = 47h
quinethazone ROA
oral
metolazone characteristics
10x more potent than HCTZ
indapamide characteristics
20x more potent than HCTZ
thiazide diuretics ADEs (overall)
depletion phenomena
retention phenomena
metabolic changes
hypersensitivity&other
thiazide diuretics depletion phenomena
hypokalemia
hypochloremic alkalosis
dilutional hyponatremia
hypomagnesemia
thiazide diuretics retention phenomena
hyperuricemia
hypercalcemia
thiazide diuretics metabolic changes
hyperglycemia
hyperlipidemia
hyper secretion of renin
hyper secretion of aldosterone
thiazide diuretics hypersensitivities&other ADEs
fever rash pupura pancreatitis sialadentitis withdrawal edema
aldosterone antagonists MOA
bind to aldosterone receptor in the cytoplasm and prevent its translocation to the nucleus: reduce ENAC channels
aldosterone antagonists effect on electrolyte excretion
increase excretion: -Na+ decrease excretion: -K+ (K sparing) -H+
spironolactone characteristics
aldosterone antagonist
pro-drug
extensively metabolized into canrenone (longer half-life)
spirinolactone ADEs
hyperkalemia (combo w/thiazide)
gynecomastia
hirsutism
uterine bleeding
eplenerone characteristics
aldosterone antagonist
less ADEs than spironolactone
aldosterone antagonists clinical uses
diuretic (combo w/HCTZ)
CHF
cirrhosis
K-sparing diuretics MOA
inhibit ENAC in sodium load segment of distal tubule
K-sparing diuretics effect on electrolyte excretion
increase excretion: -Na+ decrease excretion -K+ -H+
K-sparing diuretics clinical uses
diuretic (combo w/HCTZ)
hyperuricemia
risk of K+ depletion
K-sparing diuretics ADEs
hyperkalemia
megaloblastic anemia in patients w/cirrhosis
Tx of cirrhosis
spirinolactone
add loop diuretic if GFR50mL/min
K-sparing diuretics contraindications
significant renal insufficiency
K+ retaining conditions
Tx of chronic renal failure
loop diuretic
Tx of nephrotic syndrome
loop diuretic
Tx of moderate/severe CHF
loop diuretic
Tx of mild CHF w/GFR>50
thiazide
Tx of mild CHF w/GFR
loop diuretic